¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (2ÀÏÂ÷) : 2024-04-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (2ÀÏÂ÷) : 2024-04-26
±³À°ÀÏÀÚ : 2024-04-26
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ ¼­¿ï (ÁöÇÏ2Ãþ, ÁöÇÏ1Ãþ, 1Ãþ, 4Ãþ)

±³À°ÁÖÁ¦ : ¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (2ÀÏÂ÷)

ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : À̽ÿÂ
¿¬¶ôó : 02-3452-7291  

À̸ÞÀÏ : gbcc@intercom.co.kr

±³À°Á¾·ù : ¿Ü°ú, ¼ºÇü¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ÀÇÇб³À°, ÀÇ·á°æ¿µ

Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 30 ½Ã°£ 27ºÐ

¼¼ºÎ¼ö°­·á : 800,000¿ø  

ºñ°í [Á¶±âµî·Ï(2023.11.01-2024.02.01)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 400,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 500,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 150,000[»çÀüµî·Ï(2024.02.02-2024.04.05)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 480,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 600,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 200,000[ÇöÀåµî·Ï(2024.04.25-2024.04.27)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 640,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 800,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 250,000*http://gbcc.kr/Contents.asp?LoadPage=Instruction&Tap=B


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 08:00~08:45 [Satellite Symposium 2: Novartis] Ribociclib, Pushing the Boundary of CDK4/6 Inhibitor Soo Jung Lee(Kyungpook National Univ. Chilgok Hospital, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 08:45~09:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 09:00~09:25 [Junior Doctors Forum] Experiences with Successfully Organizing and Operating Education Programs Yazan Masannat(Broomfield Hospital, Mid & South Essex NHS Trust, United Kingdom)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 09:25~09:50 [Junior Doctors Forum] Fifteen-Year Journey of ASTRRA Trial Woochul Noh(Konkuk Univ. Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 09:00~09:25 [Symposium 4: Immunotherapy Going Beyond the Current Limits] Tailoring Post-Neoadjuvant Treatment in TNBC-Current Treatment and Future Perspectives Sung Hoon Sim(National Cancer Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 09:25~09:50 [Symposium 4: Immunotherapy Going Beyond the Current Limits] Overcoming Resistance of Immunotherapy in TNBC - Mechanism and Novel Treatment Soo-Chin Lee(National Univ. Cancer Institute, Singapore (NCIS), Singapore)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 09:50~10:15 [Symposium 4: Immunotherapy Going Beyond the Current Limits] Expanding Immunotherapy Beyond TNBC - New Strategy in HER2 and ER Positive Breast Cancer Jee Hyun Kim(Seoul National Univ. Bundang Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 09:00~09:20 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Addressing Sexual Health Disturbance During Endocrine Therapy: Unique Challenges Among Various Age Groups Tara Sanft(Yale School of Medicine, U.S.A.)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 09:20~09:40 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Current Therapeutic Options for Fertility Preservation: Challenges Ahead Matteo Lambertini(Univ. of Genova - IRCCS Policlinico San Martino Hospital , Italy)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 09:40~10:00 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Leveraging Bone Health Issue in Women Receiving Endocrine Therapy: Practical Applications and Future Perspectives So-Youn Jung(National Cancer Center, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 10:00~10:15 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 09:00~09:25 [Symposium 5: Local Tumor Control in Metastatic Breast Cancer] Role of SBRT in Oligometastasis and Oligoprogression Jee Suk Chang(Yonsei Cancer Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 09:25~09:50 [Symposium 5: Local Tumor Control in Metastatic Breast Cancer] Toilet RT in Symptomatic Advanced Breast Cancer Haeyoung Kim(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 09:50~10:15 [Symposium 5: Local Tumor Control in Metastatic Breast Cancer] Optimal RT Approach for Intracranial Metastasis Yutaro Koide(Aichi Cancer Center Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 09:00~09:25 [Nursing Session 1: Present and Future of Breast Cancer Specialist Nurse] The Experience of Breast Cancer Practice Nurses Insook Lee(Changwon National Univ., Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 09:25~09:50 [Nursing Session 1: Present and Future of Breast Cancer Specialist Nurse] Present and Future of Specialist Breast Cancer Care Nurses Jayoung Ahn(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 09:50~10:15 [Nursing Session 1: Present and Future of Breast Cancer Specialist Nurse] Best Practice of Advanced Nurse Practitioner in Breast Cancer Patient Care Byong Hee Jeon(Yonsei Univ. Health System, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:00~09:08 [Oral Presentation 5] VITAMIN D SUPPLEMENTATION HAS A POSITIVE EFFECT ON PATHOLOGIC COMPLETE RESPONSE: A PROSPECTIVE RANDOMISED STUDY Enver Ozkurt(Istanbul Demiroglu Bilim University, Republic of Turkiye)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:08~09:16 [Oral Presentation 5] RFA FOR EARLY BREAST CANCER, WHICH HAS RECENTLY BECOME COVERED BY MEDICAL INSURANCE IN JAPAN Masato Takahashi(Hokkaido University Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:16~09:24 [Oral Presentation 5] ASSESSING THE CUMULATIVE INCIDENCE OF CARDIAC EVENTS AND MAJOR ADVERSE CARDIAC EVENTS IN BREAST CANCER PATIENTS AFTER RADIATION THERAPY Tae Hyun Kim(Seoul National Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:24~09:32 [Oral Presentation 5] RELATIONSHIP OF IMMEDIATE BREAST RECONSTRUCTION AND THE DEVELOPMENT OF LYMPHEDEMA IN BREAST CANCER PATIENTS WITH RADIOTHERAPY Soon Woo Hong(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:32~09:40 [Oral Presentation 5] COMPARISON OF POST-RADIOTHERAPY SIDE EFFECTS BETWEEN MODERATELY HYPOFRACTIONATED AND ULTRA-HYPOFRACTIONATED WHOLE-BREAST IRRADIATION FOR BREAST CANCER: AN ANALYSIS OF A PROSPECTIVE COHORT STUDY Tae Hoon Lee(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:40~09:48 [Oral Presentation 5] ASSOCIATION BETWEEN GENOMIC FEATURES AND RADIATION RESPONSE IN METASTATIC BREAST CANCER PATIENTS UNDERGOING PALLIATIVE RADIOTHERAPY Hyeonseok Choi(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:48~09:56 [Oral Presentation 5] BREAST OUTCOMES OF REPEAT LUMPECTOMY IN PATIENTS WITH IPSILATERAL BREAST TUMOR RECURRENCE (IBTR) WITH OR WITHOUT RADIOTHERAPY: A COMPREHENSIVE ANALYSIS Eunju Shin(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:56~10:04 [Oral Presentation 5] EFFICACY AND SAFETY OF RESPIRATORY MOTION MANAGEMENT USING CONTINUOUS POSITIVE AIRWAY PRESSURE IN RADIOTHERAPY FOR BREAST CANCER : A PROSPECTIVE TRIAL Jung Bin Park(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 10:04~10:12 [Oral Presentation 5] CLINICOPATHOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPLICATIONS OF SUBTYPES IN DUCTAL CARCINOMA IN SITU: A RETROSPECTIVE ANALYSIS" Soo Youn Bae(The Catholic Univ. of Korea, Seoul St. Mary)

Åä·Ð 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 10:05~10:55 [Junior Doctors Debate] Can We Omit Radiation Therapy for Stage I, Luminal-Type Breast Cancer Undergoing a Breast-Conserving Surgery? Han-Byoel Lee(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 10:55~11:45 [Junior Doctors Debate] Should Contralateral Risk-Reducing Mastectomy Be Offered for All Breast Cancer Patients with a Pathologic BRCA Mutation? Tristen Park(Yale School of Medicine, U.S.A.)

ÈÞ½Ä 04¿ù 26ÀÏ 10:15~10:30 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 10:30~10:55 [Symposium 6: Tumor Heterogeneity and Dynamics in Breast Cancer: Unveiling Insights through Tissue and Liquid Biopsies] Therapy Induced Tumor Evolution Represents a Novel Therapeutic Target Gordon Mills(Oregon Health Sciences, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 10:55~11:20 [Symposium 6: Tumor Heterogeneity and Dynamics in Breast Cancer: Unveiling Insights through Tissue and Liquid Biopsies] Spatial and Temporal Dynamics in the Tumor Microenvironment through Immunotherapy Christina Curtis(Stanford Univ., U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 11:20~11:45 [Symposium 6: Tumor Heterogeneity and Dynamics in Breast Cancer: Unveiling Insights through Tissue and Liquid Biopsies] Serial Circulating Tumor DNA Landscape Portraying Clonal Evolution Pedram Razavi(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 10:30~10:50 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Overview on the Treatment Diversity for Breast Cancer Worldwide (WHO) Benjamin Anderson(Univ. of Washington, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 10:50~11:05 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Asian Data on the Treatment Diversity Takashi Ishikawa(Tokyo Medical Univ., Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 11:05~11:20 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Closing the Gap in Radiotherapy Access in Asia Mei Ling Yap(Univ. of New South Wales, Australia)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 11:20~11:35 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Age and National Disparities in the Decision-Making Process of Breast Cancer Patients Hee Jeong Kim(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 11:35~11:45 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 10:30~10:55 [Education Session 4: Less is More in Breast Cancer: Radiation Oncologists Timothy Whelan(McMaster Univ., Canada)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 10:55~11:20 [Education Session 4: Less is More in Breast Cancer: Radiation Oncologists Jeanny Kwon(Chungnam National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 11:20~11:45 [Education Session 4: Less is More in Breast Cancer: Radiation Oncologists Isabelle Kindts(AZ Groeninge, Belgium)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 10:30~10:55 [Nursing Session 2: Managements of Hair Loss and Skin Change for Breast Cancer Patients] Management of Skin Changes in Breast Cancer Patients Kyungmin Na(Daerim St. Mary)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 10:55~11:20 [Nursing Session 2: Managements of Hair Loss and Skin Change for Breast Cancer Patients] Effectiveness of Cooling Cap to Prevent Persistent Chemotherapy-Induced Alopecia Among Patients with Breast Cancer: A Randomized Controlled Trial Juhee Cho(SAIHST, Sungkyunkwan Univ., Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 11:20~11:45 [Nursing Session 2: Managements of Hair Loss and Skin Change for Breast Cancer Patients] Experience of Scalp Cooling Among Breast Cancer Nayeon Kim(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 10:30~10:55 [Session on Digital Health: The New Era of Digital Leading Innovation in Healthcare] Tech & Patient-Centric Cancer Care Eunsu Park(Lunit Care, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 10:55~11:20 [Session on Digital Health: The New Era of Digital Leading Innovation in Healthcare] HRS: Standard-Based Multi-Institutional Research Platform Soo-Yong Shin(Kakao Healthcare, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 11:20~11:45 [Session on Digital Health: The New Era of Digital Leading Innovation in Healthcare] Digital Healthcare 2024: Age of Generative AI Koon-Ho Rha(Naver Healthcare, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 11:45~12:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 12:00~12:45 [Plenary Lecture 3] Lobular Carcinoma - Current Concepts and Controversies Tari King(Dana-Farber Brigham Cancer Center, U.S.A.)

ÈÞ½Ä 04¿ù 26ÀÏ 12:45~13:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 13:00~13:45 [Satellite Symposium 3: MSD Korea] The Promising Role of Pembrolizumab in Transforming the Landscape for eTNBC Jin Seok Ahn(Samsung Medical Center, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 13:45~14:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 14:00~14:45 [Plenary Lecture 4] Origins, Evolution, and Clinical Implications of the Integrative Breast Cancer Subtypes Christina Curtis(Stanford Univ., U.S.A.)

ÈÞ½Ä 04¿ù 26ÀÏ 14:45~15:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 15:00~15:25 [Symposium 7: Neoantigen-Based Personalized Therapy] Neoantigen Analysis Sangwoo Kim(Yonsei Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 15:25~15:50 [Symposium 7: Neoantigen-Based Personalized Therapy] Neoantigen-Targeted Vaccine Soonmyung Paik(Theragen Bio, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 15:50~16:15 [Symposium 7: Neoantigen-Based Personalized Therapy] Neoantigen-Targeted Cell Therapy Hee Jin Lee(ASAN Medical Center, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 15:00~15:20 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Breast Conserving Surgery in Breast Cancer with BRCA1/2 Mutation Carriers Tristen Park(Yale School of Medicine, U.S.A.)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 15:20~15:40 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Is All Unilateral Breast Cancer with BRCA1/2 Mutation Carriers Recommended Contralateral Risk Reducing Mastectomy? Isabel T. Rubio(Clinica Universidad de Navarra, Spain)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 15:40~16:00 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Risk Reducing Mastectomy Beyond BRCA1/2 Mutation Carriers Sung-Won Kim(Daerim St. Mary)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:00~16:15 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 15:00~15:25 [Education Session 5: Toxicity of Novel Agents: A Call for Attention] Antibody Drug Conjugates Janice Tsang(The Univ. of Hong Kong, Hong Kong )

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 15:25~15:50 [Education Session 5: Toxicity of Novel Agents: A Call for Attention] Targeted Therapeutics in Hormone Positive Breast Cancers Yoon-Sim Yap(National Cancer Centre Singapore, Singapore)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 15:50~16:15 [Education Session 5: Toxicity of Novel Agents: A Call for Attention] Immunotherapies: Short and Long Term Kyoung Eun Lee(Ewha Womans Univ. Mokdong Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 15:00~15:20 [Session on OPBS] The Future of Oncoplastic Surgery: Innovations and Challenges in the Age of Personalized Breast Cancer Surgery Mee-Hoong See(Faculty of Medicine, Univ. Malaya, Malaysia)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 15:20~15:40 [Session on OPBS] Oncoplastic Surgery in the Modern Era: Balancing Surgical Outcomes with Patient Satisfaction Jeeyeon Lee(Kyungpook National Univ. Chilgok Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 15:40~16:00 [Session on OPBS] Considerations for Immediate Breast Reconstruction in Patients at High Risk of Radiation Therapy Tomoyuki Yano(Cancer Institute Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 16:00~16:15 [Session on OPBS] Surgical Difficulty of Nipple-Sparing Mastectomy and Reconstruction Based on Mastectomy Incision Location Hyun Ho Han(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 15:00~15:40 [GBCC-CACA Joint Session: The Strategy of HER-2 Positive Breast Cancer or New Drugs of Metastatic Breast Cancer] Advancements in Targeted Therapies: Managing HER2+ Metastatic Breast Cancer in Chinese Patients Pengfei Qiu(Shandong Cancer Hospital and Institute, China)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 15:40~16:15 [GBCC-CACA Joint Session: The Strategy of HER-2 Positive Breast Cancer or New Drugs of Metastatic Breast Cancer] Exploring Emerging Strategies: Addressing Triple-Negative Metastatic Breast Cancer in Korean Patients Koung Jin Suh(Seoul National Univ. Bundang Hospital, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 16:15~16:30 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 16:30~16:55 [Symposium 8: Antibody Drug Conjugates: Reshaping the Landscape of Breast Cancer Treatment] Antibody-Drug Conjugates: The Evolution of Development and Current Landscape in Breast Cancer Kyong Hwa Park(Korea Univ. Anam Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 16:55~17:20 [Symposium 8: Antibody Drug Conjugates: Reshaping the Landscape of Breast Cancer Treatment] Unresolved Problem in Real-World Practice: Toxicities and Management of Brain Metastases Chun-Yu Liu(National Yang Ming Chiao Tung University, Taiwan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 17:20~17:45 [Symposium 8: Antibody Drug Conjugates: Reshaping the Landscape of Breast Cancer Treatment] Future Directions: Resistance Mechanism of ADCs and Strategies to Overcome Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center, U.S.A.)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:30~16:37 [Special Session: Debate Session] Do we Really Need to Use Neoadjuvant IO in ER+, eBC? Jee Hung Kim(Gangnam Severance Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:37~16:44 [Special Session: Debate Session] Do we Really Need to Use Neoadjuvant IO in ER+, eBC? Dae-Won Lee(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:44~17:04 [Special Session: Debate Session] Discussion 1 ()

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 17:04~17:11 [Special Session: Debate Session] What Is the Role of Adjuvant IO After Achieving pCR in eTNBC Following Neoadjuvant IO Treatment? Jee Hung Kim(Gangnam Severance Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 17:11~17:18 [Special Session: Debate Session] What Is the Role of Adjuvant IO After Achieving pCR in eTNBC Following Neoadjuvant IO Treatment? Dae-Won Lee(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 17:18~17:45 [Special Session: Debate Session] Discussion 2 ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 16:30~16:55 [Education Session 6: Estrogen, Obesity, and Sarcopenia: Biology and Life Style] Overview Estrogen Pathway and Association with Obesity in Breast Cancer Jennifer Ligibel(Dana-Farber Cancer Institute, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 16:55~17:20 [Education Session 6: Estrogen, Obesity, and Sarcopenia: Biology and Life Style] Effect of Adjuvant Treatment on Obesity, Sarcopenia in Breast Cancer Patients Young-Jin Suh(The Catholic Univ. of Korea, St. Vincent)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 17:20~17:45 [Education Session 6: Estrogen, Obesity, and Sarcopenia: Biology and Life Style] The Role of Obesity and Sarcopenia in Anti-Cancer Immunotherapy Yen-Shen Lu(National Taiwan Univ. Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 16:30~16:55 [Session on HBOC] Long-Term Outcome of BRCA1/2 Mutation with Breast Cancer in Asia Ava Kwong(The Univ. of Hong Kong, Hong Kong )

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 16:55~17:20 [Session on HBOC] Is It Time BRCA1/2 Genetic Test as a Companion Diagnosis of Breast Cancer? Seigo Nakamura(Showa Univ. School of Medicine, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 17:20~17:45 [Session on HBOC] Gastric Cancer Risk and Management in BRCA1/2 Mutation Yoon Young Choi(Soonchunhyang Univ. Hospital Bucheon, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 16:30~16:50 [GBCC-JBCS Joint Session] De-Escalation Therapy for Low-Risk HER2-Positive Early-Stage Breast Cancer Kazuki Nozawa(Aichi Cancer Center Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 16:50~17:10 [GBCC-JBCS Joint Session] Prognostic Impact of Adjuvant Endocrine Therapy by Age for Patients with T1a/bN0M0 ER-Positive and HER2-Negative Breast Cancer Yuko Takahashi(Okayama Univ. Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 17:10~17:30 [GBCC-JBCS Joint Session] Cohort Study of Asian Breast Cancer Patients with BRCA 1/2 Mutation (KoREa-BSG 06) Chihwan Cha(Hanyang Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 17:30~17:45 [GBCC-JBCS Joint Session] Prospective Single-Arm Study of Endocrine Therapies with Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients with Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25) Sung Gwe Ahn(Gangnam Severance Hospital, Korea)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (2ÀÏÂ÷) : 2024-04-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³â Çѱ¹½Å°æ¾È°úÇÐȸ Workshop : 2024-04-27
´ÙÀ½±Û 2024 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2024-04-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 0 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 1 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 0 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 1 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 0 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 1 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 0 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 2 2024-04-29
20605 ´ë±¸ ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2024-06-20 0 0 2024-04-29
20604 °­¿ø Á¦171ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â ¿¬¼ö±³À° : 2024-06-19 0 0 2024-04-29
20603 °æ±â Á¦16ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦½ÉÆ÷Áö¾ö : 2024-06-19 0 2 2024-04-29
20602 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 0 4 2024-04-29
20601 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-06-16 0 1 2024-04-29
20600 ¼­¿ï 2024 Á¦ 2ȸ ¿¬¼¼´ëÇб³ ¼öºÎ ¹× »óÁö ½ÉÆ÷Áö¾ö : 2024-06-16 0 0 2024-04-29
20599 ¼­¿ï ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2024 »êºÎÀΰú¹Ì¼º³â¿¬¼ö°­Á : 2024-06-16 0 0 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷